Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2004 2
2008 4
2009 2
2012 1
2013 2
2014 3
2015 6
2016 5
2017 3
2018 3
2019 4
2020 6
2021 7
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

45 results
Results by year
Filters applied: . Clear all
Page 1
Showing results for median as[au]
Your search for Meziani AS[au] retrieved no results
Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study.
Chalkidou A, Macmillan T, Grzeda MT, Peacock J, Summers J, Eddy S, Coker B, Patrick H, Powell H, Berry L, Webster G, Ostler P, Dickinson PD, Hatton MQ, Henry A, Keevil S, Hawkins MA, Slevin N, van As N. Chalkidou A, et al. Among authors: van as n. Lancet Oncol. 2021 Jan;22(1):98-106. doi: 10.1016/S1470-2045(20)30537-4. Lancet Oncol. 2021. PMID: 33387498
FINDINGS: Between June 15, 2015, and Jan 30, 2019, 1422 patients were recruited from 17 hospitals in England. The median age of the patients was 69 years (IQR 62-76), and the most common primary tumour was prostate cancer (406 [28.6%] patients). Median follow-up was …
FINDINGS: Between June 15, 2015, and Jan 30, 2019, 1422 patients were recruited from 17 hospitals in England. The median age of the p …
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Busse W, et al. Among authors: van as a. J Allergy Clin Immunol. 2001 Aug;108(2):184-90. doi: 10.1067/mai.2001.117880. J Allergy Clin Immunol. 2001. PMID: 11496232 Clinical Trial.
Beclomethasone dipropionate reduction was significantly greater with omalizumab treatment than with placebo (median 75% vs 50% [P <.001]), and beclomethasone dipropionate discontinuation was more likely with omalizumab (39.6% vs 19.1% [P <.001]). ...
Beclomethasone dipropionate reduction was significantly greater with omalizumab treatment than with placebo (median 75% vs 50% [P &lt …
Early Postoperative Results of On-Pump Coronary Endarterectomy: Is Gender a Risk Factor?
Eris C, Engin M, Sunbul SA, As AK, Erdolu B. Eris C, et al. Among authors: as ak. Heart Surg Forum. 2021 Jul 28;24(4):E662-E669. doi: 10.1532/hsf.3929. Heart Surg Forum. 2021. PMID: 34473028
RESULTS: Of the 141 patients who underwent CE combined with on-pump CABG, 95 (67.3%) were male, and median age was 66 years (range 58 to 71.2). Of the 141 patients who underwent isolated on-pump CABG, 99 (70.2%) were males, and median age was 63 years (range 41 to 8 …
RESULTS: Of the 141 patients who underwent CE combined with on-pump CABG, 95 (67.3%) were male, and median age was 66 years (range 58 …
Stereotactic Body Radiotherapy for Primary Prostate Cancer.
Kothari G, Loblaw A, Tree AC, van As NJ, Moghanaki D, Lo SS, Ost P, Siva S. Kothari G, et al. Among authors: van as nj. Technol Cancer Res Treat. 2018 Jan 1;17:1533033818789633. doi: 10.1177/1533033818789633. Technol Cancer Res Treat. 2018. PMID: 30064301 Free PMC article.
In patients with low- to intermediate-risk disease, excellent biochemical relapse-free survival outcomes have been reported, albeit with relatively short median follow-up times. These promising early results, coupled with the enormous potential cost savings and implication …
In patients with low- to intermediate-risk disease, excellent biochemical relapse-free survival outcomes have been reported, albeit with rel …
Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer.
Patel PH, Chaw CL, Tree AC, Sharabiani M, van As NJ. Patel PH, et al. Among authors: van as nj. World J Urol. 2019 Dec;37(12):2615-2621. doi: 10.1007/s00345-019-02873-w. Epub 2019 Jul 25. World J Urol. 2019. PMID: 31346760 Free PMC article.
Nine patients were castrate resistant and 42 patient's hormone sensitive at the time of SBRT. Median follow-up was 23 months. Median PFS was 24 months in hormone-sensitive patients and 3 months in castrate-resistant patients. ...CONCLUSIONS: In this study, patients …
Nine patients were castrate resistant and 42 patient's hormone sensitive at the time of SBRT. Median follow-up was 23 months. Medi
Consolidative durvalumab outcomes in stage III non-small cell lung cancer in a multi-centre study.
A K, H S, W H, As F, P WP, A R. A K, et al. Among authors: as f. Cancer Treat Res Commun. 2021;29:100496. doi: 10.1016/j.ctarc.2021.100496. Epub 2021 Nov 27. Cancer Treat Res Commun. 2021. PMID: 34864586 Free article.
RESULTS: Of the total 63 patients, 27 (43%), 16 (25%), 8 (13%), and 12 (19%) patients in the PD-L1 50%, PD-L1 1-49%, PD-L1 <1%, and PD-L1 unknown groups (reported separately), respectively. With the median follow-up of 17.0 months, our multivariable Cox analysis suggest …
RESULTS: Of the total 63 patients, 27 (43%), 16 (25%), 8 (13%), and 12 (19%) patients in the PD-L1 50%, PD-L1 1-49%, PD-L1 <1%, and PD-L1 …
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study.
Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Byrne F, Cerrone M, Schmitt AM, Joharatnam-Hogan N, Shum B, Tippu Z, Rzeniewicz K, Boos LA, Harvey R, Carlyle E, Edmonds K, Del Rosario L, Sarker S, Lingard K, Mangwende M, Holt L, Ahmod H, Korteweg J, Foley T, Bazin J, Gordon W, Barber T, Emslie-Henry A, Xie W, Gerard CL, Deng D, Wall EC, Agua-Doce A, Namjou S, Caidan S, Gavrielides M, MacRae JI, Kelly G, Peat K, Kelly D, Murra A, Kelly K, O'Flaherty M, Dowdie L, Ash N, Gronthoud F, Shea RL, Gardner G, Murray D, Kinnaird F, Cui W, Pascual J, Rodney S, Mencel J, Curtis O, Stephenson C, Robinson A, Oza B, Farag S, Leslie I, Rogiers A, Iyengar S, Ethell M, Messiou C, Cunningham D, Chau I, Starling N, Turner N, Welsh L, van As N, Jones RL, Droney J, Banerjee S, Tatham KC, O'Brien M, Harrington K, Bhide S, Okines A, Reid A, Young K, Furness AJS, Pickering L, Swanton C; Crick COVID19 consortium, Gandhi S, Gamblin S, Bauer DL, Kassiotis G, Kumar S, Yousaf N, Jhanji S, Nicholson E, Howell M, Walker S, Wilkinson RJ, Larkin J, Turajlic S. Fendler A, et al. Among authors: van as n. Nat Cancer. 2021 Dec;2:1321-1337. doi: 10.1038/s43018-021-00274-w. Epub 2021 Oct 27. Nat Cancer. 2021. PMID: 34950880 Free PMC article. Clinical Trial.
Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT vs solid cancers against both WT and VOCs. In comparison with individuals without cancer, patients with haematological, but not solid, malignancies had reduced NAb …
Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT vs solid cancers agains …
Decreased Human Leukocyte Antigen DR on Circulating Monocytes Expression After Severe Pediatric Trauma: An Exploratory Report.
Cour-Andlauer F, Morrow BM, McCulloch M, Javouhey E, Lecour S, van As S, Remy S, Monneret G, Argent AC. Cour-Andlauer F, et al. Among authors: van as s. Pediatr Crit Care Med. 2021 May 1;22(5):e314-e323. doi: 10.1097/PCC.0000000000002604. Pediatr Crit Care Med. 2021. PMID: 33137010
INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We included 36 children. Median (interquartile range) age and Injury Severity Score were 7 years (4.9-10.5 yr) and 25 years (22.7-30 yr), respectively. Blood samples (n = 83) for standardized human leukocyte antigen-DR on …
INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We included 36 children. Median (interquartile range) age and Injury Severity Sco …
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.
Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Byrne F, Cerrone M, Schmitt AM, Joharatnam-Hogan N, Shum B, Tippu Z, Rzeniewicz K, Boos LA, Harvey R, Carlyle E, Edmonds K, Del Rosario L, Sarker S, Lingard K, Mangwende M, Holt L, Ahmod H, Korteweg J, Foley T, Bazin J, Gordon W, Barber T, Emslie-Henry A, Xie W, Gerard CL, Deng D, Wall EC, Agua-Doce A, Namjou S, Caidan S, Gavrielides M, MacRae JI, Kelly G, Peat K, Kelly D, Murra A, Kelly K, O'Flaherty M, Dowdie L, Ash N, Gronthoud F, Shea RL, Gardner G, Murray D, Kinnaird F, Cui W, Pascual J, Rodney S, Mencel J, Curtis O, Stephenson C, Robinson A, Oza B, Farag S, Leslie I, Rogiers A, Iyengar S, Ethell M, Messiou C, Cunningham D, Chau I, Starling N, Turner N, Welsh L, van As N, Jones RL, Droney J, Banerjee S, Tatham KC, O'Brien M, Harrington K, Bhide S, Okines A, Reid A, Young K, Furness AJS, Pickering L, Swanton C; Crick COVID-19 Consortium, Gandhi S, Gamblin S, Bauer DLV, Kassiotis G, Kumar S, Yousaf N, Jhanji S, Nicholson E, Howell M, Walker S, Wilkinson RJ, Larkin J, Turajlic S; CAPTURE Consortium. Fendler A, et al. Among authors: van as n. Nat Cancer. 2021 Dec;2(12):1305-1320. doi: 10.1038/s43018-021-00274-w. Epub 2021 Oct 27. Nat Cancer. 2021. PMID: 35121899
Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT than those with solid cancers against both SARS-CoV-2 WT and VOC. ...
Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT than those with solid c …
Physiotherapy in children hospitalized with traumatic brain injury in a South African tertiary paediatric hospital.
Corten L, van As AB, Rahim S, Kleinsmith J, Kleyn A, Kwinana T, Ndaba N, Sillito E, Smith JT, Williams N, Figaji A. Corten L, et al. Among authors: van as ab. Physiother Res Int. 2020 Oct;25(4):e1860. doi: 10.1002/pri.1860. Epub 2020 Jun 18. Physiother Res Int. 2020. PMID: 32557970
METHODS: A retrospective folder review of all children (n = 130, median 5.37 years [IQR 1.88-7.88]) admitted in 2016 with a primary diagnosis of TBI was conducted at a tertiary paediatric hospital. ...Children involved in road traffic accidents, presenting with severe diff …
METHODS: A retrospective folder review of all children (n = 130, median 5.37 years [IQR 1.88-7.88]) admitted in 2016 with a primary d …
45 results